153 related articles for article (PubMed ID: 12424552)
21. Time course of prepulse inhibition disruption induced by dopamine agonists and NMDA antagonists: effects of drug administration regimen.
Li M; He W; Chen J
Pharmacol Biochem Behav; 2011 Sep; 99(3):509-18. PubMed ID: 21600239
[TBL] [Abstract][Full Text] [Related]
22. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
van den Buuse M; Gogos A
J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
[TBL] [Abstract][Full Text] [Related]
24. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
Pietraszek M; Gravius A; Schäfer D; Weil T; Trifanova D; Danysz W
Neuropharmacology; 2005 Jul; 49(1):73-85. PubMed ID: 15992582
[TBL] [Abstract][Full Text] [Related]
25. Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding.
Levin ED; Tizabi Y; Rezvani AH; Caldwell DP; Petro A; Getachew B
Brain Res; 2005 Apr; 1041(2):132-42. PubMed ID: 15829222
[TBL] [Abstract][Full Text] [Related]
26. The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801.
Bubeníková-Valesová V; Votava M; Pálenícek T; Horácek J
Neuropharmacology; 2007 Mar; 52(4):1071-8. PubMed ID: 17196227
[TBL] [Abstract][Full Text] [Related]
27. Startle and sensorimotor gating in rats lacking CCK-A receptors.
Feifel D; Priebe K; Shilling PD
Neuropsychopharmacology; 2001 Jun; 24(6):663-70. PubMed ID: 11331146
[TBL] [Abstract][Full Text] [Related]
28. Reduced effects of amphetamine on prepulse inhibition of startle in gastrin-deficient mice.
van den Buuse M; van Driel IR; Samuelson LC; Pijnappel M; Martin S
Neurosci Lett; 2005 Jan; 373(3):237-42. PubMed ID: 15619550
[TBL] [Abstract][Full Text] [Related]
29. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine.
Hashimoto K; Fujita Y; Horio M; Kunitachi S; Iyo M; Ferraris D; Tsukamoto T
Biol Psychiatry; 2009 Jun; 65(12):1103-6. PubMed ID: 19217074
[TBL] [Abstract][Full Text] [Related]
30. "Typical" but not "atypical" antipsychotic effects on startle gating deficits in prepubertal rats.
Martinez ZA; Platten A; Pollack E; Shoemaker J; Ro H; Pitcher L; Geyer MA; Swerdlow NR
Psychopharmacology (Berl); 2002 Apr; 161(1):38-46. PubMed ID: 11967629
[TBL] [Abstract][Full Text] [Related]
31. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition.
Shilling PD; Richelson E; Feifel D
Behav Brain Res; 2003 Jul; 143(1):7-14. PubMed ID: 12842291
[TBL] [Abstract][Full Text] [Related]
32. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.
Swerdlow NR; Eastvold A; Karban B; Ploum Y; Stephany N; Geyer MA; Cadenhead K; Auerbach PP
Psychopharmacology (Berl); 2002 May; 161(2):189-201. PubMed ID: 11981599
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme (ACE) interacts with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice.
van den Buuse M; Zheng TW; Walker LL; Denton DA
Neurosci Lett; 2005 May 20-27; 380(1-2):6-11. PubMed ID: 15854741
[TBL] [Abstract][Full Text] [Related]
34. Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons.
Swerdlow NR; Stephany N; Shoemaker JM; Ross L; Wasserman LC; Talledo J; Auerbach PP
Psychopharmacology (Berl); 2002 Oct; 164(1):82-92. PubMed ID: 12373422
[TBL] [Abstract][Full Text] [Related]
35. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat.
Klamer D; Zhang J; Engel JA; Svensson L
Behav Brain Res; 2005 Apr; 159(1):95-103. PubMed ID: 15795002
[TBL] [Abstract][Full Text] [Related]
36. SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats.
de Jong IE; van den Buuse M
Neuropharmacology; 2006 Sep; 51(3):438-46. PubMed ID: 16740279
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.
Jones CK; Eberle EL; Shaw DB; McKinzie DL; Shannon HE
J Pharmacol Exp Ther; 2005 Mar; 312(3):1055-63. PubMed ID: 15574685
[TBL] [Abstract][Full Text] [Related]
38. Prepulse inhibition in fawn-hooded rats: increased sensitivity to 5-HT1A receptor stimulation.
Martin S; Lawrence AJ; van den Buuse M
Eur Neuropsychopharmacol; 2004 Oct; 14(5):373-9. PubMed ID: 15336298
[TBL] [Abstract][Full Text] [Related]
39. Lesions of the rat entopeduncular nucleus further deteriorate N-methyl-D-aspartate receptor antagonist-induced deficient prepulse inhibition.
Lütjens G; Krauss JK; Schwabe K
Neurosci Lett; 2012 Feb; 508(1):27-30. PubMed ID: 22178862
[TBL] [Abstract][Full Text] [Related]
40. Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats.
Kohnomi S; Suemaru K; Goda M; Choshi T; Hibino S; Kawasaki H; Araki H
Brain Res; 2010 Sep; 1353():152-8. PubMed ID: 20673759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
